Press Releases

SonaCare Medical to collaborate with Invivo on using MRI Fusion Software with Sonablate System

New fusion collaboration adds additional compatibility for magnetic resonance / Sonablate ultrasound fusion for prostate HIFU planning

CHARLOTTE, N.C., May 19, 2015 -- SonaCare Medical (SCM) , a world leader in minimally - invasive high intensity focused ultrasound (HIFU) technologies , announced plans to work towards a collaboration with Invivo Corporation, a worldwide leader in the development and manufacture of magnetic resonance imaging (MRI) clinical solutions,

to use Invivo software to fuse a preoperative magnetic resonance imaging data set with an intraoperative ultrasound dataset generated by SCM’s transrectal Sonablate prostate ablation system. T he combination would expand the options Sonablate physicians have to use MR guidance to target precisely areas in the prostate slated for ablation .

According to Mark Carol, M.D., CEO of SonaCare, “F using MR images with live ultrasound images allows intraoperative identification and targeting of regions of the prostate not ordinarily seen under operative ultrasound. This process of image fusion provides an improved ability for urologists to plan and target more precisely specific regions of prostate tissue. Adding fusion technology to the ablative capabilities of Sonablate makes it easier for tissue - preserving options, such as focal therapy, to be applied to the prostate. We are pleased to have gained another top quality fusion strategic partner in Invivo in order to enhance further the treatment experience for physicians and patients."

Studies have shown multi - parametric MRI to be a n accurate method for identifying regions of abnormal prostate tissue . A n annotated and segmented preoperative multi - parametric MRI dataset can be used to guide a targeted biopsy by fusing the MRI to an intraoperative ultrasound dataset generated at the time of biopsy. A dding this same fusion functionally to Sonablate allows an ablation to be targeted in a similar manner , a step considered by many urologists to be critical for the delivery of minimally invasive , tissue preserving, or focal, prostate ablations. 

“We look forward to providing Sonablate customers with the best technology available for image visualization and analysis," said Thomas Tynes , Senior Director, Strategy & Business Development at Invivo Corporation . “ Today , several hundred Healthcare facilities around the world are using Invivo ’s integrated portfolio of Prostate Oncology Solutions to better visualize and diagnose prostate cancer early. This includes our market - leading DynaCAD advanced prostate visualization and analysis software along with our most recent addition – the UroNav Fusion Biopsy System . With the growing adoption of Invivo’s Prostate Oncology Solutions and increasing interest in prostate focal therapy , we feel that our mutual customers would benefit greatly from the use of our MRI/US fusion software with the Sonablate 500. The addition of Invivo’s fusion software is a natural next step to creating a truly integrated, MRI /US solution to better support and guide the treatment of prostate cancer . ” said Mr. Tynes 

About Sonablate 500

Sonablate® 500 has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 49 countries outside the U.S. and is pending De Novo submission review by the FDA.  


About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.

For additional information, visit www.SonaCareMedical.com 

COMPANY CONTACT:
SonaCare Medical, LLC
Erica Griffith (704) 936-1834, This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward Looking Statements. 
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.